Clinical Trial Results:
The role of Qutenza (topical capsaicin 8%) in the treatment of chronic pain from critical ischaemia in patients with end stage renal failure
Summary
|
|
EudraCT number |
2012-001586-32 |
Trial protocol |
GB |
Global end of trial date |
01 Jul 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
24 Jan 2019
|
First version publication date |
24 Jan 2019
|
Other versions |
|
Summary report(s) |
Paper |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
GN12RE072
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
NHS Greater Glasgow and Clyde
|
||
Sponsor organisation address |
Dalnair Street, Glasgow, United Kingdom,
|
||
Public contact |
Maureen Travers, NHS Greater Glasgow and Clyde, 44 1412116389, Maureen.Travers@ggc.scot.nhs.uk
|
||
Scientific contact |
Maureen Travers, NHS Greater Glasgow and Clyde, 44 1412116389, Maureen.Travers@ggc.scot.nhs.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
15 Oct 2015
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
01 Jul 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Does Qutenza (topical capsaicin 8%) reduce the chronic pain from digital critical ischaemia in patients with end stage renal failure?
|
||
Protection of trial subjects |
Single treatment with study drug. Direct follow-up and contact with clinical/ research team.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Dec 2012
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 22
|
||
Worldwide total number of subjects |
22
|
||
EEA total number of subjects |
22
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
22
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
Patient recruited between 30/4/13- 6/3/14 | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
Referral by clinical team. Screening completed by research team based on information from clinical team, patient and review of clinical notes | ||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
Overall trial (overall period)
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Not applicable
|
||||||||||||
Blinding used |
Not blinded | ||||||||||||
Blinding implementation details |
NA
|
||||||||||||
Arms
|
|||||||||||||
Arm title
|
Treatment | ||||||||||||
Arm description |
Qutenza-single application | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
Qutenza
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Transdermal system
|
||||||||||||
Routes of administration |
Transdermal use
|
||||||||||||
Dosage and administration details |
Patch- single application
|
||||||||||||
|
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Treatment
|
||
Reporting group description |
Qutenza-single application | ||
Subject analysis set title |
Painful critical ischaemia
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
ESRD with painful critical ischaemia
|
|
|||||||
End point title |
Difference in VAS at 12 weeks [1] | ||||||
End point description |
|||||||
End point type |
Primary
|
||||||
End point timeframe |
12 weeks
|
||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Retrospective documentation |
|||||||
|
|||||||
No statistical analyses for this end point |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
12 weeks
|
||
Assessment type |
Non-systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
MedDRA | ||
Dictionary version |
10.0
|
||
Frequency threshold for reporting non-serious adverse events: 0% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: Retrospective documentation |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Retrospective entry |